Jazz Reports Results of JZP-258 in a P-III Study to Treat Cataplexy and Excessive Daytime Sleepiness in Patients with Narcolepsy

 Jazz Reports Results of JZP-258 in a P-III Study to Treat Cataplexy and Excessive Daytime Sleepiness in Patients with Narcolepsy

Jazz Receives FDA Approval for Xyrem’s (sodium oxybate) sNDA to Treat Cataplexy or Excessive Daytime Sleepiness in Pediatric Patients with Narcolepsy

Shots:                                                                                                                                                                

  • The P-III study involves assessing of JZP-258 vs PBO in 201 patients in ratio (1:1) with narcolepsy prior treated with sodium oxybate and naïve to sodium oxybate with/out anti-cataplectic treatments
  • The P-III study resulted in meeting its 1EPs & 2EPs i.e, reduction in the weekly number of cataplexy attacks and Epworth Sleepiness Scale (ESS) score respectively
  • JZP-258 is a novel oxybate product candidate with a unique composition of cations resulting in 92% less sodium than Xyrem (sodium oxybate), currently being evaluated to treat cataplexy and excessive daytime sleepiness in narcolepsy and idiopathic hypersomnia

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Jazz Pharmaceutical

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post